Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 crossover study of amifampridine phosphate in congenital myasthenic syndromes
2018-000358-23Phase 3Terminated
- Sponsor
- Catalyst Pharmaceuticals
- Start
- Dec 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of amifampridine in congenital myasthenic syndrome (CMS) (2 arms), sponsored by Catalyst Pharmaceuticals. Primary endpoints: Efficacy of amifampridine phosphate compared with placebo and Overall safety and tolerability. Started Dec 2018; status: terminated.
02
Drugs
amifampridine
03
Conditions
congenital myasthenic syndrome (CMS)
Beyond the preview
Go deeper on 2018-000358-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-000358-23.